arrow
I

Isabel Blancas

granada) and medicine department
H指数:16
被引数:1,127

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer

EL1SSAR前瞻性IIIb期研究初步结果:PD-L1阳性晚期三阴性乳腺癌患者一线阿替利珠单抗联合白蛋白结合型紫杉醇治疗的疗效评估

2026-06-080
OAAI
A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study☆

一种基于曲妥珠单抗–帕妥珠单抗和T-DM1的病理反应适应策略在HER2阳性早期乳腺癌中的应用:PHERGain-2研究☆

2026-05-060
OA
Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: the PHENOMENAL phase 2 study

脂质体伊立替康在HER2阴性乳腺癌和脑转移患者中的应用:PHENOMENAL II期研究

2025-12-040
PRE
Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial

预防曲拉鲁单抗govitecan相关中性粒细胞减少症和腹泻在HER2阴性晚期乳腺癌患者中的效果(PRIMED):一项开放标签、单臂、Ⅱ期临床试验

2025-07-010
PRE
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
2025-06-040
OAAI
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases

TUXEDO-4: 曲妥珠单抗-deruxtecan治疗HER2-low乳腺癌伴新发或进展性脑转移的II期研究

2025-02-280
OAAI
ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2-ABC) with aggressive disease criteria

ABIGAIL:一项随机Ⅱ期研究,评估阿贝西利联合内分泌治疗(ET),在有或无短疗程诱导紫杉醇的情况下,用于符合侵袭性标准、既往未接受治疗的激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌(HR+/HER2-ABC)患者。

2024-09-013
PRE
Efficacy and safety of ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in older patients (pts) with HR+/HER2-early breast cancer (EBC) in NATALEE

来那替尼(RIB)联合非甾体类芳香化酶抑制剂(NSAI)在NATALEE研究中,对激素受体阳性、人表皮生长因子受体2阴性早期乳腺癌(EBC)老年患者(pts)的疗效与安全性。

2024-09-011
PRE
Abemaciclib for treating patients with HR+/HER2-metastatic breast cancer: a real-world study in France, Italy and Spain

Abemaciclib用于治疗HR /HER2-metastatic乳腺癌患者: 法国,意大利和西班牙的一项现实研究

2024-08-080
OAAI
Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study

新的遗传变异解释了临床实施DPYD基因型指导的氟嘧啶治疗后的严重不良药物事件: 一项观察性研究

2024-07-190
OAAI
SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA trial
2022-05-010
OA
ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)
2022-05-010
PRE